FDA Says Safety Concerns May Negate Any Oral Dosing Advantage For GSK’s Anemia Treatment

When a drug’s biggest advantage becomes its potential downfall: The agency worries that chronic kidney disease patients not receiving dialysis may have worse outcomes on GSK’s anemia treatment daprodustat compared to ESA because of less patient safety monitoring as a result of the drug’s oral administration.